國立高雄大學圖資館 |

Language: English

Back

Polyglutamine disorders

Nobrega, Clevio.

Polyglutamine disorders

Record Type:	Electronic resources : Monograph/item
Title/Author:	Polyglutamine disordersedited by Clevio Nobrega, Luis Pereira de Almeida.
other author:	Nobrega, Clevio.
Published:	Cham :Springer International Publishing :2018.
Description:	viii, 469 p. :ill. (some col.), digital ;24 cm.
Contained By:	Springer eBooks
Subject:	Nervous systemDiseases
Online resource:	http://dx.doi.org/10.1007/978-3-319-71779-1
ISBN:	9783319717791$q(electronic bk.)

Polyglutamine disorders
Polyglutamine disorders[electronic resource] /edited by Clevio Nobrega, Luis Pereira de Almeida. - Cham :Springer International Publishing :2018. - viii, 469 p. :ill. (some col.), digital ;24 cm. - Advances in experimental medicine and biology,v.10490065-2598 ;. - Advances in experimental medicine and biology ;946..

This book provides a cutting-edge review of polyglutamine disorders. It primarily focuses on two main aspects: (1) the mechanisms underlying the pathologies' development and progression, and (2) the therapeutic strategies that are currently being explored to stop or delay disease progression. Polyglutamine (polyQ) disorders are a group of inherited neurodegenerative diseases with a fatal outcome that are caused by an abnormal expansion of a coding trinucleotide repeat (CAG), which is then translated in an abnormal protein with an elongated glutamine tract (Q) To date, nine polyQ disorders have been identified and described: dentatorubral-pallidoluysian atrophy (DRPLA); Huntington's disease (HD); spinal-bulbar muscular atrophy (SBMA); and six spinocerebellar ataxias (SCA 1, 2, 3, 6, 7, and 17) The genetic basis of polyQ disorders is well established and described, and despite important advances that have opened up the possibility of generating genetic models of the disease, the mechanisms that cause neuronal degeneration are still largely unknown and there is currently no treatment available for these disorders. Further, it is believed that the different polyQ may share some mechanisms and pathways contributing to neurodegeneration and disease progression.

ISBN: 9783319717791$q(electronic bk.)

Standard No.: 10.1007/978-3-319-71779-1doiSubjects--Topical Terms:

302262
Nervous system
--Diseases

LC Class. No.: RC346.4

Dewey Class. No.: 616.8

Polyglutamine disorders
LDR:02293nmm a2200313 a 4500 001 531610
003 DE-He213
005 20180821135311.0
006 m d
007 cr nn 008maaau
008 181113s2018 gw s 0 eng d
020 $a 9783319717791$q(electronic bk.)
020 $a 9783319717784$q(paper)
024 7 $a 10.1007/978-3-319-71779-1 $2 doi
035 $a 978-3-319-71779-1
040 $a GP $c GP
041 0 $a eng
050 4 $a RC346.4
072 7 $a PSAN $2 bicssc
072 7 $a MED057000 $2 bisacsh
082 0 4 $a 616.8 $2 23
090 $a RC346.4 $b .P782 2018
245 0 0 $a Polyglutamine disorders $h [electronic resource] / $c edited by Clevio Nobrega, Luis Pereira de Almeida.
260 $a Cham : $b Springer International Publishing : $b Imprint: Springer, $c 2018.
300 $a viii, 469 p. : $b ill. (some col.), digital ; $c 24 cm.
490 1 $a Advances in experimental medicine and biology, $x 0065-2598 ; $v v.1049
520 $a This book provides a cutting-edge review of polyglutamine disorders. It primarily focuses on two main aspects: (1) the mechanisms underlying the pathologies' development and progression, and (2) the therapeutic strategies that are currently being explored to stop or delay disease progression. Polyglutamine (polyQ) disorders are a group of inherited neurodegenerative diseases with a fatal outcome that are caused by an abnormal expansion of a coding trinucleotide repeat (CAG), which is then translated in an abnormal protein with an elongated glutamine tract (Q) To date, nine polyQ disorders have been identified and described: dentatorubral-pallidoluysian atrophy (DRPLA); Huntington's disease (HD); spinal-bulbar muscular atrophy (SBMA); and six spinocerebellar ataxias (SCA 1, 2, 3, 6, 7, and 17) The genetic basis of polyQ disorders is well established and described, and despite important advances that have opened up the possibility of generating genetic models of the disease, the mechanisms that cause neuronal degeneration are still largely unknown and there is currently no treatment available for these disorders. Further, it is believed that the different polyQ may share some mechanisms and pathways contributing to neurodegeneration and disease progression.
650 0 $a Nervous system $x Diseases $x Genetic aspects. $3 302262
650 1 4 $a Biomedicine. $3 273648
650 2 4 $a Neurosciences. $3 211508
650 2 4 $a Neurology. $3 211583
650 2 4 $a Gene Function. $3 456568
700 1 $a Nobrega, Clevio. $3 703665
700 1 $a Pereira de Almeida, Luis. $3 806162
710 2 $a SpringerLink (Online service) $3 273601
773 0 $t Springer eBooks
830 0 $a Advances in experimental medicine and biology ; $v 946. $3 557559
856 4 0 $u http://dx.doi.org/10.1007/978-3-319-71779-1
950 $a Biomedical and Life Sciences (Springer-11642)